Yonatan Resnick

Real-World Analysis of Adverse Events in Patients With Triple-Negative Breast Cancer Receiving Therapy per KEYNOTE-522

Mara Lacy Hofherr, Andrew A. Davis, Spenser January, Farah Raheem et autres

PURPOSE Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Early-stage, high-risk patients with TNBC are treated with chemotherapy and pembrolizumab per the KEYNOTE-522 regimen. This report examines real-world clinical effectiveness and toxicity of this regimen. METHODS This 19-site retrospective …

us (code pays fourni par la source)

Implementation of a Model Program at an Independent Community Oncology Practice for the Outpatient Administration of B-Cell Maturation Antigen–Directed Bispecific Antibody Step-Up Doses

Yonatan Resnick, Patrick Boland, John P. Winters

Regulatory approval of B-cell maturation antigen (BCMA)-CD3 bispecific antibodies (BsAbs) has revolutionized the treatment of patients with heavily pretreated relapsed or refractory multiple myeloma. Label-recommended premedications and step-up dose (SUD) regimens are used to mitigate the incidence and severity of serious adverse …

us (code pays fourni par la source)

Venous thromboembolism prevention program implementation in a community oncology practice: a cohort study

Steven Ades, Yonatan Resnick, Jacob Barker, Karlyn A. Martin et autres

Background: While national guidelines recommend Venous Thromboembolism (VTE) risk assessment in cancer outpatients and consideration of pharmacologic prophylaxis in high-risk patients, prophylaxis rates are low in community oncology practices. A successful model for guideline implementation (the Vermont Model, VM) is validated in …

us (code pays fourni par la source)

Abstract PS14-06: Real-World Analysis of Adverse Events in Patients with Triple Negative Breast Cancer Receiving Therapy per KEYNOTE-522

Mara Lacy Hofherr, Katherine Clifton, Spenser E. January, Emily Owen et autres

Abstract Title: Real-world analysis of adverse events in patients with triple-negative breast cancer receiving therapy per KEYNOTE-522 Background: KEYNOTE-522 was a randomized, double-blind, placebo-controlled phase 3 trial which resulted in the FDA approval of pembrolizumab with neoadjuvant chemotherapy for patients (pts) with …

us, ie, in (code pays fourni par la source)

Abstract PS14-02: Real-world analysis comparing Black and White patients with triple-negative breast cancer receiving therapy per KEYNOTE-522

Mara Lacy Hofherr, Andrew A. Davis, Spenser E. January, Emily Owen et autres

Abstract Abstract Title: Real-world analysis comparing Black and White patients with triple-negative breast cancer receiving therapy per KEYNOTE-522 Background: KEYNOTE-522 was a randomized, double-blind, placebo-controlled phase 3 trial which resulted in the FDA approval of pembrolizumab with neoadjuvant chemotherapy for patients with …

us, ie, in, pe (code pays fourni par la source)

Venous Thromboembolism (VTE) Prevention Program Implementation in a Community Oncology Practice: A Cohort Study

Steven Ades, Yonatan Resnick, Jacob Barker, Karlyn A. Martin et autres

us (code pays fourni par la source)

PB0940 Guideline Implementation Successes and Barriers to Prevent Cancer Associated Thrombosis in Community and Rural Cancer Clinics

Steven Ades, Yonatan Resnick, Juliet N. Barker, Heidi M. Feldman et autres

Background: Intensification of asparaginase treatment in pediatric-inspired chemotherapy regimens for adults with acute lymphoblastic leukemia (ALL) has improved survival, but also increased venous thromboembolism (VTE) risk with incidences reported up to 30%.The pathogenesis of VTE in ALL remains poorly understood, especially in …